La Palma Intercommunity Hospital Acute Care Hospital (Medicare Certified) Location: 7901 Walker Street, La Palma, California 90623 Ratings: Phone: (714) 670-7400 |
News Archive
A shift upward in the number of children treated by hospitals and outpatient facilities nationwide has created a spike in the demand for pediatric nurses, resulting in high pay and exceptional benefits for these positions.
The bacterium that causes Legionnaires' disease remains difficult to track. French researchers have now developed a new technique that should allow living representatives of this dangerous pathogen to be detected much more quickly than with conventional methods. As they report in the journal Angewandte Chemie, samples are exposed to an azide-modified compound that the pathogen specifically incorporates into its shell, which is made of saccharide units. A fluorescent marker attached to the azide groups is used to identify the pathogen.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient has a specific genotype - homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor.
The American College of Radiology (ACR) states that imaging cuts in the Obama Administration's deficit reduction proposal would restrict patient access to care and may actually raise Medicare costs. The ACR urges the Joint Select Committee on Deficit Reduction to reject the administration's imaging recommendations and work with ACR and other imaging stakeholders to create policies that ensure safe, appropriate care, promote quality and protect patient access.
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
› Verified 9 days ago